Artificial Intelligence in Healthcare—Will Machines Soon Make Health Economists Obsolete?

Published Nov 12, 2018

Advances in Technology are Transforming the Field of Health Economics and Outcomes Research

 Barcelona, Spain—12 November 2018—ISPOR, the professional society for health economics and outcomes research, held a session this morning at ISPOR Europe 2018, “Will Machines Soon Make Health Economists Obsolete?” [IP3], that explored the impact of machine learning on health economics. Advances in information technology (IT) and the availability of health data are revolutionizing the field of health economics and outcomes research (HEOR). In this session, speakers discussed how IT advances may impact the field and asked the provocative question, “Will artificial intelligence enable payers, providers, and patients to conduct their own HEOR analysis without the expertise of health economists?” Speakers included:
  • Moderator: David Thompson, PhD, Syneos Health, Boston, MA, USA
  • Gerry Oster, PhD, Policy Analysis Inc, Brookline, MA, USA
  • Bill Marder, PhD, MA, IBM Watson Health, Cambridge, MA, USA
  • Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK
The field of HEOR has grown tremendously in the past 25 years with the development of methodologic techniques that help address challenging analytic issues with the steady increases in computing power. Advances in IT, data storage, cloud-based computing, and artificial intelligence are creating an environment where the analytic expertise of health economists may become less critical to generate insights for health system stakeholders. This type of transformative change can currently be seen in pharmacoepidemiology in the US Food and Drug Administration’s (FDA’s) Sentinel Initiative that generates safety surveillance data on a semi-automatic basis. Dr Marder described how machine learning can automate analyses of patient-level databases. Dr Oster explained how economic modeling can be facilitated through web-based graphical user interfaces without the need for programming expertise. Dr Drummond offered the contrarian perspective and argued that health economists are still critical to the field despite these technological advances. ISPOR is recognized globally as the leading professional society in HEOR and its role in improving healthcare decisions. ISPOR Europe 2018 is the leading HEOR conference in Europe and draws more than 5000 healthcare stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, and patient engagement organizations. Additional information on ISPOR Europe 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBarcelona.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×